The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.
A decade of exploring the cancer epigenome—biological and translational implications
Open accessAbstract
The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, disruption of chromosomal topology and oncogene insulation may be more generally relevant to methylator phenotypes observed in colorectal and renal cell carcinomas, leukemia and other malignancies28.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that enhanced histone acetylation induced by HDACi allowed the overexpression of genes involved in cell cycle arrest such as cyclin-dependent kinase inhibitors or the growth arrest and DNA damage-inducible protein GADD45 gene family (11, 28, 40, 45-49).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among them, novel selective benzamide-based HDAC1/2 inhibitors have been described that exhibit greater than 100-fold selectivity relative to other HDACs (11, 28).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It has previously been shown that HDAC inhibitors such as SAHA and MS-275 promote cell cycle arrest and apoptosis”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among activated genes that subside with pulsed HDACi administration are genes known to be powerful effectors of cell cycle arrest in multiple cell types and may promote apoptosis (11, 50).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“Three general processes have major effects on cancer initiation and progression. First, discrete somatic mutations lead to tumor suppressor loss-of-function and oncoprotein gain-of-function [1]; second, epigenetic alterations change patterns of gene expression [2]; and third, alterations in the tumor microenvironment also lead to broad changes in gene expression [3].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,205
Flagged first, then by citations
3 of the 166 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Allis, C., Jenuwein, T. & Reinberg, D. Epigenetics (ed. Caparros, M.) (Cold Spring Harbor Laboratory Press, 2007).
- Allis, C. D., Jenuwein, T, Reinberg, D. Overview and concepts (Cold Spring Harbor Laboratory Press, New York, 2007).
- Gilbert, M. R. et al. in ASCO Annual Meeting 2011 Abstr. 2006. (University of Texas M. D. Anderson Cancer Center, Chicago, 2011).
Cited by
Sorted by citations
Items 501–600 of 1,001
Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer
Piqué, L., de Paz, A. M., Piñeyro, D., Martínez‐Cardús, A., de Moura, M. C., Llinàs‐Arias, P., Setién, F., Miragaya, J. G., González‐Suárez, E., Sigurðsson, S., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0936-x · Cited by 75
Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
Khan, M. A., Tania, M., & Fu, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.007 · Cited by 82
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 78
Phytochemicals from Cruciferous Vegetables, Epigenetics, and Prostate Cancer Prevention
Watson, G. W., Beaver, L. M., Williams, D. E., Dashwood, R. H., & Ho, E. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9504-4 · Cited by 78
Katoh, M. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00061 · Cited by 78
Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer
Ding, P., Ge, G., Gong, Y., Zhan, Y., He, S., Guan, B., Li, Y., Xu, Z., Hao, H., He, Z., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0527-7 · Cited by 78
Summerbell, E. R., Mouw, J. K., Bell, J. S. K., Knippler, C. M., Pedro, B. A., Arnst, J. L., Khatib, T. O., Commander, R., Barwick, B. G., Konen, J. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6197 · Cited by 77
Fang, M., Hutchinson, L., DENG, A. C., & Green, M. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525619113 · Cited by 77
Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma
Daugaard, I., Dominguez, D., Kjeldsen, T. E., Kristensen, L. S., Hager, H., Wojdacz, T. K., & Hansen, L. L. (2016) · Scientific Reports · doi:10.1038/srep35807 · Cited by 77
Lungu, C., Pinter, S., Broche, J., Rathert, P., & Jeltsch, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00457-z · Cited by 77
Mediterranean Diet: Prevention of Colorectal Cancer
Donovan, M. G., Selmin, O. I., Doetschman, T. C., & Romagnolo, D. F. (2017) · Frontiers in Nutrition · doi:10.3389/fnut.2017.00059 · Cited by 82
The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond
Rohwer, N., Zasada, C., Kempa, S., & Cramer, T. (2012) · Oncogene · doi:10.1038/onc.2012.510 · Cited by 78
5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer
Uribe‐Lewis, S., Stark, R., Carroll, T. D., Dunning, M., Bachman, M., Ito, Y., Stojic, L., Halim, S., Vowler, S. L., Lynch, A. G., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0605-5 · Cited by 75
Cervino, G., Fiorillo, L., Herford, A. S., Romeo, U., Bianchi, A., Crimi, S., D’Amico, C., Stefano, R. D., Troiano, G., Santoro, R., et al. (2019) · Disease Markers · doi:10.1155/2019/8040361 · Cited by 76
Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression
Yang, G., Shi, R., & Zhang, Q. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218162 · Cited by 78
DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
Laranjeira, A. B. A., Hollingshead, M. G., Nguyen, D., Kinders, R. J., Doroshow, J. H., & Yang, S. X. (2023) · Scientific Reports · doi:10.1038/s41598-023-32509-4 · Cited by 80
Islam, F., Gopalan, V., Wahab, R., Smith, R. A., & Lam, A. K.-Y. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.04.007 · Cited by 76
Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer
Yeh, C.-M., Shay, J., ZENG, T.-C., Chou, J.-L., Huang, T. H. ‐., Lai, H., & Chan, M. W. Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2627 · Cited by 76
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 77
Chatterjee, A., Stockwell, P. A., Rodger, E. J., Duncan, E. J., Parry, M. F., Weeks, R. J., & Morison, I. M. (2015) · Scientific Reports · doi:10.1038/srep17328 · Cited by 75
Human DNMT1 transition state structure
Du, Q., Wang, Z., & Schramm, V. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522491113 · Cited by 83
Intergenerational epigenetic inheritance of cancer susceptibility in mammals
Lesch, B. J., Tóthová, Z., Morgan, E. A., Liao, Z., Bronson, R. T., Ebert, B. L., & Page, D. C. (2019) · eLife · doi:10.7554/elife.39380 · Cited by 76
Roche, J., Nasarre, P., Gemmill, R. M., Baldys, A., Pontis, J., Korch, C. T., Guilhot, J., Ait‐Si‐Ali, S., & Drabkin, H. A. (2013) · Cancers · doi:10.3390/cancers5020334 · Cited by 77
Portraits of TET-mediated DNA hydroxymethylation in cancer
Jeschke, J., Collignon, É., & Fuks, F. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.004 · Cited by 76
Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer
Liu, J., Li, H. R., Sun, L. L., Wang, Z., Xing, C., & Yuan, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0444-4 · Cited by 75
Wu, C.-Y., Lau, B. T., Kim, H. S., Sathe, A., Grimes, S. M., Ji, H. P., & Zhang, N. R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00911-w · Cited by 75
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
Zhang, L., Li, H., Shereda, R., Lu, Q., Weisenberger, D. J., O'Connell, C. L., Machida, K., An, W., Lenz, H., El-Khoueiry, A. B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215899 · Cited by 79
Self-citationThe Mechanism of DNA Methylation and miRNA in Breast Cancer
Ma, L., Li, C., Yin, H., Huang, J., Yu, S., Zhao, J. X., Tang, Y., Yu, M., Lin, J., Ding, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119360 · Cited by 78
Dangi-Garimella, S. Y., Sahai, V., Ebine, K., Kumar, K., & Munshi, H. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064566 · Cited by 75
Harel, S. A., Moshe, N. B. B., Aylon, Y., Bublik, D. R., Moskovits, N. B.-C., Toperoff, G., Azaiza, D., Biagoni, F., Fuchs, G., Wilder, S., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.221 · Cited by 76
Dietrich, D., Jung, M., Pützer, S., Leisse, A., Holmes, E. E., Meller, S., Uhl, B., Schatz, P., Ivascu, C., & Kristiansen, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084225 · Cited by 74
Momparler, R. L., Côté, S., Momparler, L. F., & Idaghdour, Y. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-19 · Cited by 75
dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes
Nanda, J. S., Kumar, R., & Raghava, G. P. S. (2016) · Scientific Reports · doi:10.1038/srep19340 · Cited by 75
The fate is not always written in the genes: Epigenomics in epidemiologic studies
Langevin, S. M., & Kelsey, K. T. (2013) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21762 · Cited by 75
A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition
Carmona, F. J., Dávalos, V., Vidal, E., Gómez, A., Heyn, H., Hashimoto, Y., Vizoso, M., Martínez‐Cardús, A., Sayols, S., Ferreira, H. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3659 · Cited by 74
Takeda, H., Takai, A., Inuzuka, T., & Marusawa, H. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1273-2 · Cited by 78
Larsen, L. K., Lind, G. E., Guldberg, P., & Dahl, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112657 · Cited by 74
The emerging roles of PIWI-interacting RNA in human cancers
Yu, Y., Xiao, J., & Hann, S. S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s209300 · Cited by 77
Dąbrowski, M. J., & Wojtaś, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143478 · Cited by 73
Scheller, M., Ludwig, A. K., Göllner, S., Rohde, C., Krämer, S., Stäble, S., Janssen, M., Müller, J.-A., He, L., Bäumer, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00213-9 · Cited by 73
Tet family of 5-methylcytosine dioxygenases in mammalian development
Zhao, H., & Chen, T. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.63 · Cited by 75
Cicek, M. S., Koestler, D. C., Fridley, B. L., Kalli, K. R., Armasu, S. M., Larson, M. C., Wang, C., Winham, S. J., Vierkant, R. A., Rider, D. N., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt160 · Cited by 74
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
Schiffmann, I., Greve, G., Jung, M., & Lübbert, M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1237345 · Cited by 75
Stable transgenerational epigenetic inheritance requires a DNA methylation-sensing circuit
Williams, B. P., & Gehring, M. A. (2017) · Nature Communications · doi:10.1038/s41467-017-02219-3 · Cited by 74
Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study
Jiang, C., He, S.-W., Zhang, Y., Duan, H., Huang, T., Huang, Y., Li, G., Wang, P., Ma, L., Zhou, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13622 · Cited by 75
A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer
Good, C. R., Madžo, J., Patel, B. G., Maegawa, S., Engel, N., Jelı́nek, J., & Issa, J. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx435 · Cited by 74
The Role of DNA Methylation in Renal Cell Carcinoma
Lasseigne, B. N., & Brooks, J. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0337-9 · Cited by 75
Jeltsch, A., Broche, J., & Bashtrykov, P. (2018) · Genes · doi:10.3390/genes9110566 · Cited by 79
Current paradigms in epigenetic anticancer therapeutics and future challenges
Singh, M. P., Kumar, V., Sehrawat, N., Yadav, M. K., Chaudhary, M., Upadhyay, S. K., Kumar, S., Sharma, V., Kumar, S., Dilbaghi, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.013 · Cited by 78
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 75
Rilova, E., Erdmann, A., Gros, C., Masson, V., Aussagues, Y., Poughon, V., Rajavelu, A., Jeltsch, A., Menon, Y., Novosad, N., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300420 · Cited by 76
Fu, J., Lv, H., Guan, H., Ma, X., Ji, M., He, N., Shi, B., & Hou, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-462 · Cited by 70
Ko, T. K., Javed, A., Lee, K. L., Pathiraja, T. N., Liu, X., Malik, S., Soh, S. X., Heng, X. T., Takahashi, N., Tan, J. H. J., et al. (2020) · Blood · doi:10.1182/blood.2020004834 · Cited by 72
Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer
Reang, J., Sharma, P. C., Thakur, V. K., & Majeed, J. (2021) · Biomolecules · doi:10.3390/biom11081130 · Cited by 73
Epigenetics in T‐cell acute lymphoblastic leukemia
Peirs, S., der Meulen, J. V., de Walle, I. V., Taghon, T., Speleman, F., Poppe, B. G., & Vlierberghe, P. V. (2014) · Immunological Reviews · doi:10.1111/imr.12237 · Cited by 76
Schoofs, T., Rohde, C., Hebestreit, K., Klein, H., Göllner, S., Schulze, I., Lerdrup, M., Dietrich, N., Singh, S. A., Witten, A., et al. (2012) · Blood · doi:10.1182/blood-2012-08-448860 · Cited by 71
Frau, C., Loi, R., Petrelli, A., Perra, A., Menegon, S., Kowalik, M. A., Pinna, S., Leoni, V. P., Fornari, F., Gramantieri, L., et al. (2014) · Hepatology · doi:10.1002/hep.27399 · Cited by 72
Chatterjee, A., Stockwell, P. A., Ahn, A., Rodger, E. J., Leichter, A. L., & Eccles, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.14042 · Cited by 72
Kuramoto, J., Arai, E., Tian, Y., Funahashi, N., Hiramoto, M., Nammo, T., Nozaki, Y., Takahashi, Y., Ito, N., Shibuya, A., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx005 · Cited by 72
The epigenetic landscape of age-related diseases: the geroscience perspective
Gensous, N., Bacalini, M. G., Pirazzini, C., Marasco, E., Giuliani, C., Ravaioli, F., Mengozzi, G., Bertarelli, C., Palmas, M. G., Franceschi, C., et al. (2017) · Biogerontology · doi:10.1007/s10522-017-9695-7 · Cited by 74
Long-range phasing of dynamic, tissue-specific and allele-specific regulatory elements
Battaglia, S., Dong, K., Wu, J., Chen, Z., Najm, F. J., Zhang, Y., Moore, M. M., Hecht, V. C., Shoresh, N., & Bernstein, B. (2022) · Nature Genetics · doi:10.1038/s41588-022-01188-8 · Cited by 65
Han, F., Liu, W., JIANG, X. H., Shi, X. A., Yin, L., Ao, L., Cui, Z., Li, Y., Huang, C., Cao, J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.370 · Cited by 71
Minireview: Epigenomic Plasticity and Vulnerability to EDC Exposures
Walker, C. L. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1086 · Cited by 76
Methylation analyses in liquid biopsy
Lissa, D., & Robles, A. I. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.03 · Cited by 71
Emperle, M., Adam, S., Kunert, S., Dukatz, M., Baude, A., Plass, C., Rathert, P., Bashtrykov, P., & Jeltsch, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz911 · Cited by 69
Cell-Free DNA Methylation Profiling Analysis—Technologies and Bioinformatics
Huang, J., & Wang, L. (2019) · Cancers · doi:10.3390/cancers11111741 · Cited by 71
DNA Methylation as a Therapeutic Target for Bladder Cancer
Nunes, S. P., Henrique, R., Jerónimo, C., & Paramio, J. M. (2020) · Cells · doi:10.3390/cells9081850 · Cited by 71
Davletgildeeva, A. T., & Kuznetsov, N. A. (2024) · Biomolecules · doi:10.3390/biom14091117 · Cited by 76
Bridging epigenetics and metabolism
Phang, J. M., Liu, W., & Hancock, C. N. (2013) · Epigenetics · doi:10.4161/epi.24042 · Cited by 71
Phase II trial of vorinostat in advanced melanoma
Haas, N. B., Quirt, I. C., Hotte, S. J., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0066-9 · Cited by 71
Keep‐ING balance: Tumor suppression by epigenetic regulation
Tallen, G. R. N., & Riabowol, K. T. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.011 · Cited by 70
Lund, K., Cole, J. J., VanderKraats, N. D., McBryan, T., Pchelintsev, N. A., Clark, W. A., Copland, M., Edwards, J. R., & Adams, P. D. (2014) · Genome biology · doi:10.1186/s13059-014-0406-2 · Cited by 72
Nia, A. B., & Tommasi, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-227074 · Cited by 70
Aslani, S., Mahmoudi, M., Garshasbi, M., Jamshidi, A., Karami, J., & Nicknam, M. H. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3403-x · Cited by 70
Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’?
Visal, T. H., den Hollander, P., Cristofanilli, M., & Mani, S. A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01768-9 · Cited by 72
Sato, T., Arai, E., Kohno, T., Takahashi, Y., Miyata, S., Tsuta, K., WATANABE, S.-I. I., Soejima, K., Betsuyaku, T., & Kanai, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28684 · Cited by 70
Arai, E., Sakamoto, H., Ichikawa, H., Totsuka, H., Chiku, S., Gotoh, M., Mori, T., Nakatani, T., Ohnami, S., Nakagawa, T., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28768 · Cited by 69
The influence of race and ethnicity on the biology of cancer
Henderson, B. E., Lee, N. H., Seewaldt, V. L., & Shen, H. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3341 · Cited by 68
Halby, L., Menon, Y., Rilova, E., Pechalrieu, D., Masson, V., Faux, C., Bouhlel, M. A., David‐Cordonnier, M., Novosad, N., Aussagues, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00176 · Cited by 69
Homme, R. P., Singh, M., Majumder, A., George, A. K., Nair, K., Sandhu, H. S., Tyagi, N., Lominadze, D. G., & Tyagi, S. C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01268 · Cited by 69
Rabal, O., José‐Eneriz, E. S., Agirre, X., Sánchez-Arias, J. A., Vilas‐Zornoza, A., Ugarte, A., de Miguel, I., Miranda, E., Gárate, L., Fraga, M. F., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01926 · Cited by 68
Li, Z., Xia, J., Fang, M., & Xu, Y. (2019) · Oncogenesis · doi:10.1038/s41389-019-0174-7 · Cited by 68
Νikolouzakis, Τ. Κ., Falzone, L., Lasithiotakis, K. G., Krüger‐Krasagakis, S., Kalogeraki, A. M., Sifaki, M., Spandidos, D. A., Chrysos, E., Tsatsakis, A. M., & Tsiaoussis, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092868 · Cited by 71
Yu, B., RUSSANOVA, V. R., Gravina, S., Hartley, S. W., Mullikin, J. C., Ignezweski, A., Graham, J., Segars, J. H., DeCherney, A. H., & Howard, B. H. (2015) · Oncotarget · doi:10.18632/oncotarget.2875 · Cited by 67
Vendetti, F. P., & Rudin, C. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.819337 · Cited by 68
Johnson, K. C., Koestler, D. C., Cheng, C., & Christensen, B. C. (2013) · Epigenetics · doi:10.4161/epi.27015 · Cited by 68
Usp7-dependent histone H3 deubiquitylation regulates maintenance of DNA methylation
Yamaguchi, L., Nishiyama, A., Misaki, T., Johmura, Y., Ueda, J., Arita, K., Nagao, K., Obuse, C., & Nakanishi, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-00136-5 · Cited by 69
Emerging roles of piRNAs in cancer: challenges and prospects
Cheng, Y., Wang, Q., Jiang, W., Bian, Y., Zhou, Y., Gou, A., Zhang, W., Fu, K., & Shi, W. (2019) · Aging · doi:10.18632/aging.102417 · Cited by 69
Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling
Magnani, L., & Lupien, M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.026 · Cited by 67
Gene-Specific Targeting of DNA Methylation in the Mammalian Genome
Urbano, A., Smith, J., Weeks, R. J., & Chatterjee, A. (2019) · Cancers · doi:10.3390/cancers11101515 · Cited by 67
A global assessment of cancer genomic alterations in epigenetic mechanisms
Shah, M. A., Denton, E., Arrowsmith, C. H., Lupien, M., & Schapira, M. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-29 · Cited by 71
Walker, D. L., Bhagwate, A. V., Baheti, S., Smalley, R. L., Hilker, C. A., Sun, Z., & Cunningham, J. M. (2015) · Epigenomics · doi:10.2217/epi.15.64 · Cited by 69
Raynal, N. J. ‐., Costa, E. M. D., Lee, J. T., Gharibyan, V., Ahmed, S., Zhang, H., Sato, T., Malouf, G. G., & Issa, J. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0588 · Cited by 67
Zhou, Y., Ding, B.-Z., Lin, Y., & Wang, H. (2017) · Gene · doi:10.1016/j.gene.2017.10.046 · Cited by 67
Exploiting epigenetic vulnerabilities for cancer therapeutics
Mair, B., Kubicek, S., & Nijman, S. M. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.001 · Cited by 66
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 68
Davegårdh, C., Broholm, C., Perfilyev, A., Henriksen, T. I., García-Calzón, S., Peijs, L., Hansen, N. S., Volkov, P., Kjøbsted, R., Wojtaszewski, J. F. P., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0792-x · Cited by 66
Blood-based DNA methylation signatures in cancer: A systematic review
Li, Y., Fan, Z., Meng, Y., Liu, S., & Zhan, H. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166583 · Cited by 68
Hibino, S., Saito, Y., Muramatsu, T., Otani, A., Kasai, Y., Kimura, M., & Saito, H. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.17 · Cited by 66
Sano, K., Nakajima, T., Choyke, P. L., & Kobayashi, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0633 · Cited by 66
Metadata
- Authors
- Baylin, S. B., & Jones, P. A.
- Affiliations
- Johns Hopkins University (US)
- University of Southern California (US)
- Corresponding author
- Baylin, Stephen B.
- Jones, Peter A.
- Venue
- Nature Reviews Cancer
- Published
- 2011-09-23
- Volume
- 11
- Issue
- 10
- Pages
- 726-734
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3307543
- OpenAlex
- W2041686632
- Cited by
- 2,871
- References
- 166
- Citations by year
- 2026: 105 · 2025: 107 · 2024: 130 · 2023: 148 · 2022: 179 · 2021: 207 · 2020: 175 · 2019: 209 · 2018: 192 · 2017: 233 · 2016: 241 · 2015: 248 · 2014: 288 · 2013: 231 · 2012: 171
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (R01CA043318, R37CA082422)
- National Institute of Environmental Health Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cancer epigenome, DNA methylation, chromatin, epigenetic therapy, tumor markers, cancer diagnosis and prognosis, tumor progression, DNA packaging, epigenetic enzymes, cancer metabolism, epigenetic mutations
- MeSH terms
- Animals, Humans, Neoplasms, Genome, Epigenesis, Genetic, History, 20th Century, History, 21st Century, Translational Research, Biomedical, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
